All In Biotech

BLA 125338 · Auxilium Pharms

Xiaflex

Collagenase Clostridium Histolyticum · Injection

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Feb 2, 2010

Approved uses

6

Original approval plus efficacy supplements

Registered trials

69

20 Phase 3, 1 recruiting

FAERS reports

5,433

1,380 serious, 61 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CORPORAL RUPTURE (PENILE FRACTURE) or OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE’S DISEASE Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies. In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile “popping” sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded. Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 (3.7%) XIAFLEX-treated patients [see Warnings and Precautions (5.2)] . Signs or symptoms that may reflect serious penile injury should be promptly evaluated to assess for corporal rupture or severe penile hematoma which may require surgical intervention [see Warnings and Precautions (5.2)] . Because of the...

What it is approved for

From the label in effect Sep 17, 2026.

XIAFLEX is indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord. XIAFLEX is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. XIAFLEX is a combination of bacterial collagenases indicated for the treatment of: Adult patients with Dupuytren’s contracture with a palpable cord ( 1 ) Adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy ( 1 )

Mechanism: Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits. Injection of XIAFLEX into a Dupuytren’s cord, which is comprised mostly of collagen, may result in enzymatic disruption of the cord. The signs and symptoms of Peyronie’s disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie’s plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 15, 2015 Supplement 87 · Efficacy LabelLetter
  • May 15, 2015 Supplement 85 · Efficacy LetterLabel
  • May 15, 2015 Supplement 88 · Efficacy LabelLetter
  • Oct 20, 2014 Supplement 84 · Efficacy OrphanLetterLabel
  • Dec 6, 2013 Supplement 61 · Efficacy OrphanLabelLetter
  • Feb 2, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewOther
1 products under this application
  • XIAFLEX · COLLAGENASE CLOSTRIDIUM HISTOLYTICUM 0.9MG · SOLUTION, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Collagenase Clostridium Histolyticum" as an intervention, any sponsor and status, largest first.

All 69 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,359
  • contusion671
  • swelling576
  • pain506
  • penile swelling479
  • fracture of penis465
  • penile contusion449
  • injection site pain322
  • penile pain311
  • inappropriate schedule of product administration214
  • injection site swelling213
  • condition aggravated208

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201033
2011153
201251
201320
201443
2015361
2016422
2017332
2018418
2019656
2020742
2021589
2022530
2023303
2024324
2025304
2026152

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xiaflex (Collagenase Clostridium Hist.)

2024 spending

$69.8M

Beneficiaries

4,346

6,420 claims

Per beneficiary

$16,067

$6,564.14 per unit

View as table
YearSpending
2020$30,987,013
2021$46,325,487
2022$63,949,527
2023$66,001,126
2024$69,829,348

Part B: Xiaflex (Collagenase Clostridium Hist.) · HCPCS J0775

2024 spending

$80.0M

Beneficiaries

6,999

12,522 claims

Per beneficiary

$11,431

2024 ASP limit $68.77 per unit

View as table
YearSpending
2020$55,724,586
2021$68,178,746
2022$70,414,259
2023$75,176,039
2024$80,008,759

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 84 on PubMed

Sponsor: Auxilium Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.